Study guide
2.1 Cardiovascular Pharmacotherapy
Board Certified Pharmacotherapy Specialist BCPS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction and Exam Logistics
1.1 About the BCPS Exam & BPS Specialty Board 1.2 Eligibility, Registration, and Pearson VUE Logistics 1.3 Study Strategies & Exam-Taking Skills for BCPS
2 Chapter 2: Therapeutics: Cardiovascular & Pulmonary
2.1 Cardiovascular Pharmacotherapy 2.2 Pulmonology & Respiratory Care 2.3 Critical Care & Emergency Medicine
3 Chapter 3: Therapeutics: Infectious Diseases
3.1 Infectious Diseases: Antimicrobial Stewardship & Pharmacokinetics 3.2 Infectious Diseases: Common & Severe Infections 3.3 Infectious Diseases: Specialty Infections
4 Chapter 4: Therapeutics: Renal, Endocrine & Gastrointestinal
4.1 Nephrology & Renal Pharmacotherapy 4.2 Endocrinology & Diabetes Mellitus 4.3 Gastroenterology & Hepatic Disorders
5 Chapter 5: Therapeutics: Neurology, Psychiatry & Pain Management
5.1 Pain Management & Palliative Care 5.2 Neurologic Pharmacotherapy 5.3 Psychiatric Pharmacotherapy
6 Chapter 6: Therapeutics: Special Populations
6.1 Geriatric Pharmacotherapy & Beers Criteria 6.2 Pediatric & Neonatal Pharmacotherapy 6.3 Women's Health
7 Chapter 7: Therapeutics: Oncology, Nutrition & Immunology
7.1 Oncology & Support Care 7.2 Nutrition Support 7.3 Immunology, Allergy, & Vaccine-Preventable Diseases 7.4 Urologic Disorders: BPH, Overactive Bladder, and Erectile Dysfunction
8 Chapter 8: Patient Care: Therapeutics & Patient Management
8.1 Clinical Assessment & Patient History 8.2 Clinical Pharmacokinetics: Dosing, Clearance, Vd, and TDM 8.3 Therapeutic Implementation & Medication Reconciliation 8.4 Social Determinants of Health in Treatment Planning
9 Chapter 9: Patient Care: Treatment Monitoring & Outcomes
9.1 Patient Counseling, Education, & Adherence 9.2 Treatment Monitoring: Efficacy, Targets, & Lab Interpretation 9.3 Adverse Drug Event (ADE) Detection & Management
10 Chapter 10: Professional Practice & Evidence-Based Medicine
10.1 Research Methodology & Biostatistics 10.2 Drug Literature Evaluation & Evidence-Based Application 10.3 Medication Safety, Quality of Care, & Public Health
11 Chapter 11: Professional Practice: Systems & Management
11.1 Healthcare Regulations, Standards of Care, & Collaborative Practice 11.2 Pharmacoeconomics, Cost-Benefit Analysis, & Formulary Management
2.1 Cardiovascular Pharmacotherapy
Key Takeaways Explain This Topic AI
ACC/AHA guidelines emphasize early hypertension treatment; Stage 1 requires medications if ASCVD risk ≥ 10%.
HFrEF management relies on four pillars: Beta-blockers, ARNI/ACEi/ARB, MRAs, and SGLT2 inhibitors.
A strict 36-hour washout period is necessary when switching from an ACE inhibitor to an ARNI to prevent angioedema.
Amiodarone requires extensive baseline and ongoing monitoring for pulmonary, thyroid, hepatic, and ophthalmic toxicities.
DOAC dosing in AFib relies heavily on renal function and patient specific criteria like the Apixaban 5/2.5/80/60/1.5 rule.
Last updated: July 2026
- Cardiovascular Pharmacotherapy
- Hypertension (ACC/AHA Guidelines)
The 2017 ACC/AHA guidelines redefined hypertension staging to emphasize earlier intervention. Normal blood pressure is <120/80 mmHg. Elevated BP is 120-129/<80 mmHg, treated with nonpharmacological interventions. Stage 1 hypertension is 130-139 or 80-89 mmHg. For Stage 1, clinical ASCVD or an estimated 10-year ASCVD risk ≥10% dictates the initiation of blood pressure-lowering medication alongside lifestyle changes; otherwise, lifestyle modification alone is recommended. Stage 2 hypertension is defined as BP ≥140 or ≥90 mmHg, warranting both lifestyle modification and the initiation of two BP-lowering medications from different classes if the BP is >20/10 mmHg above target.
First-line agents include Thiazide diuretics (e.g., chlorthalidone, hydrochlorothiazide), Calcium Channel Blockers (CCBs like amlodipine), and ACE inhibitors or ARBs. African American patients without heart failure or chronic kidney disease should initially receive a thiazide or CCB. In patients with CKD (stage 3 or higher or albuminuria >300 mg/day), an ACEi or ARB is recommended for renal protection regardless of race.
Drug Class Examples Key Monitoring/Clinical Pearls
Thiazides Chlorthalidone, HCTZ Monitor for hyponatremia, hypokalemia, hyperuricemia, and hypercalcemia. Chlorthalidone is preferred based on prolonged half-life and proven cardiovascular risk reduction.
CCBs (Dihydropyridines) Amlodipine, Nifedipine Peripheral edema is dose-dependent. Avoid short-acting nifedipine due to reflex tachycardia and increased MI risk.
ACEi/ARBs Lisinopril, Losartan Monitor SCr and K+ (expect up to 30% rise in SCr). Contraindicated in pregnancy and bilateral renal artery stenosis. Angioedema risk higher in Black patients (with ACEi).
Heart Failure with Reduced Ejection Fraction (HFrEF)
Guideline-directed medical therapy (GDMT) for HFrEF (LVEF ≤ 40%) focuses on four foundational pillars proven to reduce morbidity and mortality. These should be initiated rapidly and up-titrated to target doses or maximally tolerated doses.
Beta-Blockers : Only three beta-blockers have proven mortality benefit in HFrEF: bisoprolol, carvedilol, and sustained-release metoprolol succinate. They should be initiated in stable patients (euvolemic, not requiring IV inotropes). Carvedilol also blocks alpha-1 receptors, offering additional afterload reduction but more hypotension.
Renin-Angiotensin System Inhibitors : ARNI (sacubitril/valsartan) is preferred over ACEi/ARBs to further reduce morbidity and mortality. A 36-hour washout period is strictly required when switching from an ACEi to an ARNI to prevent life-threatening angioedema.
Mineralocorticoid Receptor Antagonists (MRAs) : Spironolactone or eplerenone. Essential monitoring includes potassium and renal function. Avoid initiation if K+ > 5.0 mEq/L or eGFR < 30 mL/min/1.73m2. Eplerenone is a selective antagonist and avoids gynecomastia seen with spironolactone.
SGLT2 Inhibitors : Dapagliflozin and empagliflozin reduce heart failure hospitalizations and cardiovascular death regardless of the presence of diabetes. They provide diuretic synergy but increase the risk of genitourinary infections.
Other agents like Ivabradine may be considered for patients with resting HR ≥ 70 bpm in sinus rhythm who are on maximally tolerated beta-blockers. Hydralazine/Isosorbide dinitrate is recommended for self-identified African Americans with NYHA class III-IV HFrEF receiving optimal therapy with the four pillars.
Arrhythmias: Atrial Fibrillation (AFib)
Management of AFib involves three primary considerations: rate control, rhythm control, and stroke prevention.
Rate vs. Rhythm Control : The AFFIRM trial demonstrated that rate control is generally non-inferior to rhythm control for overall mortality. Rate control is typically achieved using beta-blockers (metoprolol, esmolol), non-dihydropyridine CCBs (diltiazem, verapamil), or digoxin. Digoxin is purely negative chronotropic and positive inotropic; a narrow therapeutic index requires monitoring (target 0.5-0.9 ng/mL for HF, can be higher for AFib). Non-DHP CCBs must be avoided in patients with HFrEF due to negative inotropic effects.
Rhythm control (cardioversion and antiarrhythmic maintenance) is preferred in highly symptomatic patients, younger patients, or those with tachycardia-induced cardiomyopathy. Agents include Class IC (flecainide, propafenone - strictly avoid in structural heart disease) and Class III (amiodarone, dofetilide, sotalol).
Amiodarone Therapeutic Drug Monitoring (TDM) and Toxicity :
Amiodarone contains iodine and is highly lipophilic, with a massive volume of distribution and a half-life of 40-60 days. Toxicity monitoring is crucial:
- Pulmonary toxicity (baseline and annual CXR/PFTs)
- Thyroid toxicity (baseline and every 6 months TSH/free T4; can cause hyper- or hypothyroidism)
- Hepatotoxicity (baseline and every 6 months LFTs)
- Ophthalmic (optic neuropathy, corneal microdeposits)
Given its myriad drug interactions (CYP3A4, 2C9, P-gp inhibitor), doses of warfarin and digoxin must be preemptively reduced by 30-50% upon amiodarone initiation.
Anticoagulation (Stroke Prevention in AFib)
Stroke risk is assessed using the CHA2DS2-VASc score.
- Congestive heart failure (1)
- Hypertension (1)
- Age ≥ 75 (2)
- Diabetes (1)
- Stroke/TIA/TE (2)
- Vascular disease (1)
- Age 65-74 (1)
- Sex category female (1)
Oral anticoagulation is recommended for a score of ≥ 2 in men or ≥ 3 in women. Direct Oral Anticoagulants (DOACs: apixaban, rivaroxaban, dabigatran, edoxaban) are preferred over warfarin unless the patient has moderate-to-severe mitral stenosis or a mechanical heart valve.
Renal dosing is critical for DOACs. For example, apixaban is dosed at 2.5 mg BID if a patient has at least two of the following: Age ≥ 80, Body weight ≤ 60 kg, or Serum Creatinine ≥ 1.5 mg/dL. Rivaroxaban must be taken with the largest meal of the day to ensure absorption for the 15 mg and 20 mg doses, and should be avoided in CrCl < 15 mL/min.
Bleeding risk is assessed via the HAS-BLED score (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history/predisposition, Labile INR, Elderly >65, Drugs/alcohol). A high score (≥3) should not preclude anticoagulation but highlights the need to correct modifiable bleeding risks.